期刊文献+

抗血栓药物阿哌沙班中6种残留溶剂测定 被引量:2

Determination of Six Residual Solvents in Antithrombotic Drug Apixaban
下载PDF
导出
摘要 目的:建立气相色谱法并测定抗血栓药物阿哌沙班中的残留溶剂。方法:以二甲基亚砜为溶剂,采用Rtx-Wax(0.32 mm×30 m,2.5μm)极性毛细管柱程序升温,以氮气为载气,FID为检测器,进样口温度为225℃,检测器温度为260℃,对阿哌沙班中6种残留溶剂(三乙胺、甲醇、异丙醇、甲苯、N,N-二甲基甲酰胺、甲酰胺)进行测定。结果:各被测残留溶剂均能良好分离、各溶剂线性关系良好,精密度RSD均不超过1.50%,平均回收率为96.0%~100.0%之间。结论:本文建立的方法可用于阿哌沙班原料药中残留溶剂的测定。 Objective: To establish a gas chromatography method for the determination of residual solvents in antithrombotic drug Apixaban. Methods: Six residual solvents including triethylamine, methanol, isopropanol, methylbenzene, DMF and formamide were determined by GC with Rtx-Wax capillary column(0.32 mm×30 m×2.5 μm, 2.5 μm) and an FID detector with 260℃. Temperature of the injection port was 225℃. Results: Each solvent could be completely separated in chromatography obtained from systemic suitability test, and the calibration curves of each solvent had a good linear relationship.The RSD of precision was not more than 1.50%.The average recovery was between 96.0% and 100.0%. Conclusion: GC method can be used to determine the residual solvents of Apixaban.
出处 《中国药事》 CAS 2016年第8期796-800,共5页 Chinese Pharmaceutical Affairs
关键词 抗血栓药 抗凝药物 阿哌沙班 残留溶剂 三乙胺 甲醇 异丙醇 甲苯 二甲基甲酰胺 甲酰胺 毛细管柱气相色谱 antithrombotic drugs anticoagulant drugs Apixaban residual solvents triethylamine methanol isopropyl alcohol toluene dimethyl formamide formamide capillary column gas chromatography
  • 相关文献

参考文献13

二级参考文献101

  • 1秦立,胡昌勤,刘文英.顶空气相色谱法测定药品中残留溶剂的影响因素考察[J].药物分析杂志,2005,25(7):823-826. 被引量:40
  • 2周海钧.药品注册的国际技术要求(质量部分)[M].北京:人民卫生出版社,2001.82.
  • 3中国药典[S].2010年版.二部.附录ⅨJ.
  • 4冀亚飞,蒋健安,刘倩,等.一种抗血栓药物阿匹沙班的制备方法:中国,101967145[P].2010-09-09.
  • 5Friedman RJ,Dahl OE,Rosencher N,et al.Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty:a pooled analysis of three trials[J].Thromb Res,2010,126(3):175-182.
  • 6Eriksson BI,Dahl OE,Huo MH,et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*)[J].Thromb Haemost,2011,105(4):721-729.
  • 7Schulman S,Kearon C,Kakkar AK,et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism[J].N Engl J Med,2009,361(24):2342-2352.
  • 8Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
  • 9Wann LS,Curtis AB,Ellenbogen KA,et al.2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran):a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2011,123(10):1144-1150.
  • 10Oldgren J,Budaj A,Granger CB,et al.Dabigatran vs.placebo in patients with acute coronary syndromes on dual antiplatelet therapy:a randomized,double-blind,phase II trial[J].Eur Heart J,2011,32(22):2781-2789.

共引文献112

同被引文献21

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部